Omada Health sells virtual cardiometabolic and chronic-condition care — diabetes prevention and management, hypertension, MSK, and a GLP-1 companion program — to employers, health plans, and benefits consultants. It is one of the highest-volume B2B advertisers on LinkedIn (600+ live ads at capture), and almost the entire current push is GLP-1: “one GLP-1 partner that adapts to,” “GLP-1 fragmentation,” and a 3,000-patient GLP-1 survey. The tactic that stands out is people: Omada boosts posts from its own executives and sales team (the CEO, health-plan and account leaders) as ads, and runs a branded thought-leadership series, “Proof Points,” as article ads across GLP-1, diabetes and MSK. It rounds the mix out with distribution news (now available through OptumRx / all three major PBMs) and a live event, Horizon Day.
How Omada Health advertises: a near-total focus on GLP-1, delivered through people and proof. Typographic teaser cards (‘one GLP-1 partner that adapts to’, ‘GLP-1 fragmentation’) run mostly as boosted posts from Omada’s own executives and sales team; a branded ‘Proof Points’ article series carries clinical thought leadership across GLP-1, diabetes and MSK; a 3,000-patient survey supplies proprietary data; and distribution news (now on all three major PBMs) plus the Horizon Day event round it out.
Formats observed across 600+ live ads. Worth noting for advertisers: much of Omada’s reach comes from boosting individual employees’ posts as ads — expertise-led, not brand-broadcast — plus a named content franchise (‘Proof Points’) run for months.
| Format | What Omada Health uses it for |
|---|---|
| Single image ad | Typographic GLP-1 teaser cards and member/availability creatives |
| LinkedIn article ad | The branded “Proof Points” series across GLP-1, diabetes and MSK |
| Boosted people posts | Exec- and rep-authored posts (CEO, sales, account leaders) promoted as ads |
| Event ad | Horizon Day and LinkedIn Live sessions on GLP-1 connected care |
Live Omada Health creatives with their full ad copy (verbatim), format, theme and CTA.
"GLP-1 decisions don’t just shape benefit designs — they shape relationships. When GLP-1 costs, coverage, and expectations shift, employers need one partner that adapts to their strategy rather than forcing a single model."
"Outcome-focused care has always been the throughline in health-plan work. With GLP-1s, that focus has never mattered more — and what gets in the way is fragmentation: too many members on GLP-1s left without connected clinical support."
"Limiting GLP-1 coverage may be linked to reduced employee satisfaction, increased burnout, and greater turnover risk, leaving benefits leaders with a difficult and urgent challenge: how to help more patients succeed with GLP-1s while managing clinical complexity, patient experience, and financial sustainability. Our latest GLP-1 patient survey has answers."
"For large employers, covering GLP-1s is no longer a “yes/no” decision. These medications are reshaping health benefits at a scale we haven’t seen in decades — and large employers are defining what happens next. In this month’s Proof Points, Britt Buntman, Omada’s VP of GLP-1 & Cardiometabolic Health, unpacks what that means."
"November is #DiabetesAwarenessMonth. As a digital diabetes prevention provider over the last decade, we’ve seen first-hand how diabetes doesn’t “act” alone — Omada for Diabetes members often manage multiple chronic conditions at once, requiring care that adapts to their circumstances."
"90% of individuals living with obesity have existing musculoskeletal (MSK) concerns. What does that mean for GLP-1 care? This edition covers barriers to healthy diet and exercise for GLP-1 patients, the effects of cardiometabolic disease on the MSK system, and designing sustainable exercise plans to improve outcomes."
"Omada is now available for employers through all three largest PBMs. Real Omada members like Jackie can access cardiometabolic support alongside their GLP-1 coverage."
"Join Horizon Day 2026 for a LinkedIn Live reveal of how Omada is redefining cardiometabolic care as GLP-1s reshape the obesity treatment landscape — as concerns around access, cost, and fragmentation rise just as quickly."
Ad copy and creatives shown verbatim for commentary and analysis; they belong to Omada Health (paid for by Omada Health). Captured from the public LinkedIn Ad Library.
Omada boosts its own execs’ and reps’ posts as ads. Expertise from a named person outperforms a faceless brand post for a considered B2B buyer.
‘Proof Points’ is a reusable, named series — one template, months of topics across GLP-1, diabetes and MSK.
A proprietary 3,000-patient GLP-1 survey gives every ad something only Omada can say.
“Now available through all three major PBMs” is a proof-of-legitimacy message worth its own creative, not a footnote.
We build LinkedIn and paid programs for regulated, high-consideration healthcare buyers — measured on pipeline, not impressions.
Book a free ad auditOmada promotes virtual cardiometabolic and chronic-condition care — diabetes, hypertension, MSK and a GLP-1 companion program — to employers, health plans and benefits consultants. Its current advertising is almost entirely GLP-1 focused: connected care, reducing fragmentation, and a 3,000-patient GLP-1 survey.
Single-image typographic teaser cards (‘one GLP-1 partner that adapts to’, ‘GLP-1 fragmentation’), LinkedIn article ads for its ‘Proof Points’ content series across GLP-1/diabetes/MSK, boosted posts from its own executives and sales team, and event ads (Horizon Day). It also runs availability/distribution creative (now on all three major PBMs).
GLP-1 fragmentation and adaptability. The core argument is that GLP-1 coverage is no longer a yes/no decision, and that employers need one partner that wraps connected clinical support around the medication. Proof (a 3,000-patient survey, named clinical authors) and distribution news (OptumRx / all three PBMs) reinforce it.
Put people on the front line — Omada boosts its own execs’ and reps’ posts as ads, which reads as expertise rather than brand broadcast. Build a named content franchise (‘Proof Points’) you can run for months across topics, lead with a proprietary data point (the 3,000-patient survey), and turn distribution wins into their own campaign.